Novo Nordisk's sales and profits were both up around 30% last quarter. Its GLP-1 weight loss drug has been a driving force ...

Genmab's Q4 2024 results impress with $897.4M revenue and 29% growth. GMAB's balance sheet is strong with nearly $3 billion ...

Novo Nordisk's sales and profits soared in Q4 Last week, Novo Nordisk released its year-end results, including how it performed over the last three months of 2024.

The Zacks Consensus Estimate for R’s soon-to-be-reported quarter’s earnings has been revised downward by 0.6% in the past 60 days to $3.42 per share. Meanwhile, the Zacks Consensus Estimate ...

Right now, we’re issuing “Double Down” alerts for three incredible companies, and there may not be another chance like this anytime soon.

And the numbers speak for themselves: Right now, we’re issuing “Double Down” alerts for three incredible companies, and there may not be another chance like this anytime soon. Founded in ...

In the GLP-1 weight loss market, it's largely been a two-horse race between Eli Lilly and Novo Nordisk (NYSE: NVO). The two companies have approved weight loss drugs that are generating billions ...

Chip making firm Nvidia has launched an AI-powered platform design to help to enable users to learn sign language, known as ...

The Zacks Consensus Estimate for R’s soon-to-be-reported quarter’s earnings has been revised downward by 0.6% in the past 60 days to $3.42 per share. Meanwhile, the Zacks Consensus Estimate for ...